Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: There is a controversy about the availability of invasive treatment for esophageal/gastric varices in patients with Child-Pugh class C (CP-C) end-stage liver cirrhosis (LC). We have evaluated the validity of invasive treatment with CP-C end-stage LC patients. Methods: The study enrolled 51 patients with CP-C end-stage LC who had undergone invasive treatment. The treatment modalities included endoscopic variceal ligation in 22 patients, endoscopic injection sclerotherapy in 17 patients, and balloon-occluded retrograde transvenous obliteration (BRTO) in 12 patients. We have investigated the overall survival (OS) rates and risk factors that contributed to death within one year after treatment. Results: The OS rate in all patients at one, three, and five years was 72.6%, 30.2%, and 15.1%, respectively. The OS rate in patients who received endoscopic treatment and the BRTO group at one, three, and five years was 67.6%, 28.2% and 14.1% and 90.0%, 36.0% and 18.0%, respectively. The average of Child-Pugh scores (CPS) from before treatment to one month after variceal treatment significantly improved from 10.53 to 10.02 (P=0.003). Three significant factors that contributed to death within one year after treatment included the presence of bleeding varices, high CPS (≥11), and high serum total bilirubin levels (≥4.0 mg/dL). Conclusions: The study demonstrated that patients with a CPS of up to 10 and less than 4.0 mg/dL of serum total bilirubin levels may not have a negative impact on prognosis after invasive treatment for esophageal/gastric varices despite their CP-C end-stage LC.
Abstract
Background/Aims: There is a controversy about the availability of invasive treatment for esophageal/gastric varices in patients with Child-Pugh class C (CP-C) end-stage liver cirrhosis (LC). We have evaluated the validity of invasive treatment with CP-C end-stage LC patients. Methods: The study enrolled 51 patients with CP-C end-stage LC who had undergone invasive treatment. The treatment modalities included endoscopic variceal ligation in 22 patients, endoscopic injection sclerotherapy in 17 patients, and balloon-occluded retrograde transvenous obliteration (BRTO) in 12 patients. We have investigated the overall survival (OS) rates and risk factors that contributed to death within one year after treatment. Results: The OS rate in all patients at one, three, and five years was 72.6%, 30.2%, and 15.1%, respectively. The OS rate in patients who received endoscopic treatment and the BRTO group at one, three, and five years was 67.6%, 28.2% and 14.1% and 90.0%, 36.0% and 18.0%, respectively. The average of Child-Pugh scores (CPS) from before treatment to one month after variceal treatment significantly improved from 10.53 to 10.02 (P=0.003). Three significant factors that contributed to death within one year after treatment included the presence of bleeding varices, high CPS (≥11), and high serum total bilirubin levels (≥4.0 mg/dL). Conclusions: The study demonstrated that patients with a CPS of up to 10 and less than 4.0 mg/dL of serum total bilirubin levels may not have a negative impact on prognosis after invasive treatment for esophageal/gastric varices despite their CP-C end-stage LC.
참고문헌 (28)
- Orrego H, "Correlation of intrahepatic pressure with collagen in the Disse space and hepatomegaly in humans and in the rat", Gastroenterology, 80, pp.546~556 (1981)
- Blendis LM, "The role of hepatocyte enlargement in hepatic pressure in cirrhotic and noncirrhotic alcoholic liver disease", Hepatology, 2, pp.539~546 (1982)
- Grossman HJ, "The effect of hepatocyte enlargement on the hemodynamic characteristics of the isolated perfused rat liver preparation", Hepatology, 27, pp.446~451 (1998)
- Bhathal PS, "Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators", J Hepatol, 1, pp.325~337 (1985)
- Chao Y, "Hepatic hemodynamic features in patients with esophageal or gastric varices", J Hepatol, 19, pp.85~89 (1993)
- Hasumi A, "Causative relationship between a hyperdynamic state due to increased A-V anastomoses in the gastric wall and AGML in patients with liver cirrhosis", J Gastroenterol Hepatol, 4(Suppl 1), pp.143~145 (1989)
- Masaki M, "The destructive effects of sclerosant ethanolamine oleate on mammalian vessel endothelium", Gastroenterol Jpn, 25, pp.230~235 (1990)
- Iwase H, "Symposium on endoscopic hemostasis in gastric diseases. 2. Choice of endoscopic therapy for esophagogastric varices: aiming for safer and more effective therapy", Intern Med, 36, pp.128~129 (1997)
- D’Amico G, "Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies", J Hepatol, 44, pp.217~231 (2006)
- Genda T, "Survival in patients with Child-Pugh class C cirrhosis : analysis of the liver transplant registry in Japan", Hepatol Res, 47, pp.1155~1164 (2017)
- Kanagawa H, "Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration", J Gastroenterol Hepatol, 11, pp.51~58 (1996)
- Park JK, "Balloon-Occluded Retrograde Transvenous Obliteration(BRTO)for treatment of gastric varices : review and meta-analysis", Dig Dis Sci, 60, pp.1543~1553 (2015)
- Numata K, "Use of balloon-occluded retrograde transvenous obliteration with ethanolamine oleate for the treatment of hepatic encephalopathy in a cirrhotic patient with a large spontaneous splenorenal shunt", J Gastroenterol, 33, pp.424~427 (1998)
- Kawanaka H, "Portosystemic encephalopathy treated with balloonoccluded retrograde transvenous obliteration", Am J Gastroenterol, 90, pp.508~510 (1995)
- Saad WE, "Balloon-occluded retrograde transvenous obliteration of gastric varices : concept, basic techniques, and outcomes", Semin Intervent Radiol, 29, pp.118~128 (2012)
- Garcia-Pagán JC, "Management of gastric varices", Clin Gastroenterol Hepatol, 12, pp.919~928 (2014)[DOI]
- Tanihata H, "Changes in portal systemic pressure gradient after balloon-occluded retrograde transvenous obliteration of gastric varices and aggravation of esophageal varices", Cardiovasc Intervent Radiol, 32, pp.1209~1216 (2009)
- Choi YS, "Effect of balloon-occluded retrograde transvenous obliteration on the natural history of coexisting esophageal varices", J Clin Gastroenterol, 42, pp.974~979 (2008)
- Fukuda T, "Long-term results of balloonoccluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy", J Vasc Interv Radiol, 12, pp.327~336 (2001)
- 장세영, "Clinical outcomes of balloon-occluded retrograde transvenous obliteration for the treatment of gastric variceal hemorrhage in Korean patients with liver cirrhosis: a retrospective multicenter study", Clinical and Molecular Hepatology, 18(4), pp.368~374 (2012), 대한간학회[DOI]
- Miyamoto Y, "Balloonoccluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension", J Gastroenterol Hepatol, 18, pp.934~942 (2003)
- Akahane T, "Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration", Am J Gastroenterol, 92, pp.1026~1030 (1997)
- Uehara H, "Prediction of improved liver function after balloon-occluded retrograde transvenous obliteration : relation to hepatic vein pressure gradient", J Gastroenterol Hepatol, 27, pp.137~141 (2012)
- Park SJ, "The prevalence, risk factors, and clinical outcome of balloon rupture in balloon-occluded retrograde transvenous obliteration of gastric varices", J Vasc Interv Radiol, 21, pp.503~507 (2010)
- Arai H, "Respiratory effects of balloon occluded retrograde transvenous obliteration of gastric varices : a prospective controlled study", J Gastroenterol Hepatol, 26, pp.1389~1394 (2011)
- Choi SY, "Foam sclerotherapy using polidocanol for balloon-occluded retrograde transvenous obliteration(BRTO)", Eur Radiol, 21, pp.122~129 (2011)
- Clements W, "Variant treatment for gastric varices with polidocanol foam using balloon-occluded retrograde transvenous obliteration : a pilot study", J Med Imaging Radiat Oncol, 56, pp.599~605 (2012)
- Yoshida H, "Long-term results of partial splenic artery embolization as supplemental treatment for portal-systemic encephalopathy", Am J Gastroenterol, 100, pp.43~47 (2005)